시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
항비만약 시장 규모, 점유율, 성장 분석 : 약 유형별, 작용별, 투여별, 지역별 - 산업 예측(2025-2032년)
Anti Obesity Drugs Market Size, Share, Growth Analysis, By Drug Type, By Action, By Administration, By Region - Industry Forecast 2025-2032
상품코드 : 1630628
리서치사 : SkyQuest Technology Consulting Pvt. Ltd.
발행일 : 2025년 01월
페이지 정보 : 영문 165 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,465,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,732,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,000,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 항비만약 시장 규모는 2023년에 37억 달러로 평가되며, 2024년 46억 7,000만 달러에서 2032년에는 302억 6,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 26.3%로 성장할 전망입니다.

세계비만연맹(World Obesity Federation)은 비만 관련 비용이 50% 이상 급증하여 2025년 말까지 약 1조 2,000억 달러에 달할 것으로 예상하고 있습니다. 이러한 급격한 증가는 제약업계가 비만 대책에 효과적인 솔루션 개발에 집중하고 있음을 강조하고 있습니다. 환자 수가 증가하고 치료율이 낮게 유지되고 있으므로 신규 시장 진출기업에게는 큰 기회가 있습니다. 비만 인식 개선 노력과 지원적인 비용 상환 정책의 확립은 제품 수요를 촉진할 가능성이 높으며, COVID-19 팬데믹은 역설적으로 비만과 관련된 건강 위험 증가로 인해 보건 당국이 관리 지침을 발표함에 따라 승인된 항비만제의 판매를 촉진하고 있습니다. 역설적으로 승인된 항비만약의 판매를 촉진하고 있습니다. 또한 봉쇄로 인해 앉아서 생활하는 시간이 늘어나면서 비만 치료에 대한 수요가 증가하여 시장 성장을 가속할 수 있습니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

항비만약 시장 규모 : 약 유형별

항비만약 시장 규모 : 작용별

항비만약 시장 규모 : 투여별

항비만약 시장 규모 : 유통 채널별

항비만약 시장 규모

경쟁 정보

주요 기업 개요

결론과 권장사항

KSA
영문 목차

영문목차

Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).

The World Obesity Federation forecasts that obesity-related costs will surge by over 50%, reaching approximately $1.2 trillion by the end of 2025. This escalation emphasizes the pharmaceutical industry's focus on developing effective solutions to combat obesity. As the patient population grows and treatment rates remain low, there are significant opportunities for new entrants in the market. Initiatives aimed at educating the public about obesity and the establishment of supportive reimbursement policies are likely to drive product demand. The COVID-19 pandemic has paradoxically boosted sales of approved anti-obesity medications, as heightened health risks associated with obesity have prompted health organizations to issue management guidelines. Furthermore, increased sedentary behavior due to lockdowns has intensified the need for obesity treatments, potentially enhancing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Obesity Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti Obesity Drugs Market Segmental Analysis

Global Anti Obesity Drugs Market is segmented by Drug Type, Action, Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Prescription Drug and Over the Counter Drugs. Based on Action, the market is segmented into Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs. Based on Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti Obesity Drugs Market

The global anti-obesity drugs market is significantly driven by escalating concerns regarding effective obesity management, propelled by the alarming rise in obesity rates among populations worldwide. Currently, the World Obesity Federation reports staggering figures of approximately 650 million adults and 120 million children grappling with obesity, leading to an annual expenditure of around US$ 2 trillion for obesity-related healthcare. Furthermore, the Centers for Disease Control and Prevention (CDC) indicates that 42.5% of adults in the United States are classified as obese. This escalating awareness, particularly in emerging economies, about the necessity of timely weight management is anticipated to further fuel the demand for anti-obesity medications in the market over the coming years.

Restraints in the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market faces significant restraints, despite the increasing prevalence of obesity worldwide. Treatment rates remain low, primarily due to a lack of awareness regarding weight management and widespread misconceptions about obesity. Our research indicates that only 2% of individuals with obesity receive prescription medication for their condition, reflecting low acceptance of these drugs, which hampers market growth. Additionally, the market is constrained by the limited number of key companies focused on developing obesity treatments and the adverse effects associated with these medications, further impeding broader adoption and expansion of anti-obesity solutions.

Market Trends of the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market is witnessing a significant trend towards the development of dual-action therapeutic compounds aimed at simultaneously addressing both Type 2 diabetes mellitus and obesity. This burgeoning focus is driven by the alarming increase in obesity rates and the corresponding prevalence of Type 2 diabetes, prompting pharmaceutical companies and researchers to innovate and create effective medications that tackle these interrelated health issues. With unhealthy dietary habits, sedentary lifestyles, and a growing obese population persisting as key challenges, the market is poised for substantial growth in the coming years, presenting lucrative opportunities for stakeholders in the healthcare sector.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Anti Obesity Drugs Market Size by Drug Type & CAGR (2025-2032)

Global Anti Obesity Drugs Market Size by Action & CAGR (2025-2032)

Global Anti Obesity Drugs Market Size by Administration & CAGR (2025-2032)

Global Anti Obesity Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Global Anti Obesity Drugs Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기